Novartis Bets $1.4B on Inflammation Pathway With Tourmaline Bio Acquisition

Basel, September 9, 2025 (Novartis) -- Novartis will acquire Tourmaline Bio for $1.4 billion, adding pacibekitug—an anti-IL-6 antibody targeting inflammation in ASCVD—to its cardiovascular pipeline. Phase 2 data showed the therapy reduced inflammation by over 85% with a safety profile comparable to placebo, positioning it as a potential breakthrough where no widely used anti-inflammatory options exist. The acquisition, expected to close in late 2025, strengthens Novartis’ long-term strategy to lead in cardiovascular innovation.

Read full article here.